Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2017 Jun;23(6):762-768.
doi: 10.1002/lt.24688.

Hemophilia Liver Transplantation Observational Study

Margaret V Ragni  1 , Abhinav Humar  2 , Peter G Stock  3 , Emily A Blumberg  4 , Bijan Eghtesad  5 , John J Fung  5 , Valentina Stosor  6 , Nicholas Nissen  7 , Michael T Wong  8 , Kenneth E Sherman  9 , Donald M Stablein  10 , Burc Barin  10
Affiliations
Observational Study

Hemophilia Liver Transplantation Observational Study

Margaret V Ragni et al. Liver Transpl. 2017 Jun.

Abstract

Hepatitis C virus (HCV) infection is the leading cause of liver disease in hemophilia patients. In those with human immunodeficiency virus (HIV)/HCV coinfection, the rate of liver disease progression is greater than in HCV monoinfected individuals. Despite antiretroviral therapy, which slows HCV liver disease progression, some require transplantation. Whether transplant outcomes are worse in hemophilic (H) rather than nonhemophilic (NH) candidates is unknown. In order to determine rates and predictors of pretransplant and posttransplant survival, we conducted a retrospective observational study using United Network for Organ Sharing national transplant registry data, comparing HCV+ H and NH candidates. We identified 2502 HCV+ liver transplant candidates from 8 US university-based transplant centers, between January 1, 2004 to December 31, 2010, including 144 HIV+ (6%) and 2358 HIV-; 36 H (1%) and 2466 NH; 1213 (48%) transplanted and 1289 not transplanted. Other than male predominance and younger age, each were P < 0.001. Baseline data were comparable between H and NH. In univariate analysis, 90-day pretransplant mortality was associated with higher baseline Model for End-Stage Liver Disease (MELD; hazard ratio [HR] = 1.15; P < 0.001), lower baseline platelet count (HR = 0.9 per 25,000/µL; P = 0.04), and having HIV/HCV+ hemophilia (P = 0.003). In multivariate analysis, pretransplant mortality was associated with higher MELD (P < 0.001) and was significantly greater in HIV+ than HIV- groups (P = 0.001). However, it did not differ between HIV+ H and NH (HR = 1.7; P = 0.36). Among HIV/HCV+, posttransplant mortality was similar between H and NH, despite lower CD4 in H (P = 0.04). In conclusion, this observational study confirms that hemophilia per se does not have a specific influence on transplant outcomes and that HIV infection increases the risk of mortality in both H and NH patients. Liver Transplantation 23 762-768 2017 AASLD.

PubMed Disclaimer

Conflict of interest statement

Disclosure

The authors have no conflicts of interest to disclose.

Conflicts of Interest:

None of the authors declares any conflicts of interest.

Figures

Figure 1
Figure 1. Pre-transplant Outcomes in HIV/HCV Co-Infected Candidates
Figure 1a: Time to Death in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-death curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non hemophilic candidates, p<0.001, for overall comparison in the first 90 days post-listing. Figure 1b: Time to Transplant in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-transplant curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic candidates, p=0.26, for overall comparison in the first 90 days post-listing. Figure 1c: Time to Elevated MELD (25) in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-MELD 25 curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV-hemophilic, and HIV− non- hemophilic candidates, p=0.02, for overall comparison in the first 90 days-post- listing.
Figure 1
Figure 1. Pre-transplant Outcomes in HIV/HCV Co-Infected Candidates
Figure 1a: Time to Death in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-death curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non hemophilic candidates, p<0.001, for overall comparison in the first 90 days post-listing. Figure 1b: Time to Transplant in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-transplant curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic candidates, p=0.26, for overall comparison in the first 90 days post-listing. Figure 1c: Time to Elevated MELD (25) in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-MELD 25 curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV-hemophilic, and HIV− non- hemophilic candidates, p=0.02, for overall comparison in the first 90 days-post- listing.
Figure 1
Figure 1. Pre-transplant Outcomes in HIV/HCV Co-Infected Candidates
Figure 1a: Time to Death in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-death curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non hemophilic candidates, p<0.001, for overall comparison in the first 90 days post-listing. Figure 1b: Time to Transplant in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-transplant curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic candidates, p=0.26, for overall comparison in the first 90 days post-listing. Figure 1c: Time to Elevated MELD (25) in Liver Transplant Candidates This figure shows Kaplan-Meier time-to-MELD 25 curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV-hemophilic, and HIV− non- hemophilic candidates, p=0.02, for overall comparison in the first 90 days-post- listing.
Figure 2
Figure 2. Post-transplant Outcomes in HIV/HCV Co-Infected Recipients
Figure 2a: Time to Death in Liver Transplant Recipients This figure shows Kaplan-Meier time-to-death curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic recipients, p=0.02, for overall comparison in the first 3 years post-transplant. Figure 2b: Time to Graft Loss in Liver Transplant Recipients The figure shows Kaplan-Meier time-to-graft loss curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic recipients, p=0.02, for overall comparison in the first 3 years post-transplant.
Figure 2
Figure 2. Post-transplant Outcomes in HIV/HCV Co-Infected Recipients
Figure 2a: Time to Death in Liver Transplant Recipients This figure shows Kaplan-Meier time-to-death curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic recipients, p=0.02, for overall comparison in the first 3 years post-transplant. Figure 2b: Time to Graft Loss in Liver Transplant Recipients The figure shows Kaplan-Meier time-to-graft loss curves for all four groups, including HIV+ hemophilic, HIV+ non-hemophilic, HIV− hemophilic, and HIV− non-hemophilic recipients, p=0.02, for overall comparison in the first 3 years post-transplant.
See this image and copyright information in PMC

Comment in

Similar articles

See all similar articles

Cited by

References

    1. Ragni MV, Belle SH. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C infection. J Infect Dis. 2001;183:1112–1115. - PubMed
    1. Ragni MV, Moore CG, Soadwa K, Nalesnik MA, Zajko AB, Cortese-Hassett A, et al. Impact of HIV on liver fibrosis in men with hepatitis C infection and hemophilia. Hemophilia. 2011;17:103–111. - PMC - PubMed
    1. Ragni MV, Winkelstein A, Kingsley LA, Spero A, Lewis JH. 1986 Update of HIV seroprevalence, seroconversion, AIDS incidence and immunologic correlates of HIV infection in hemophiliacs. Blood. 1987;70:786–790. - PubMed
    1. Ragni MV, Ndimbe OK, Rice EO, Bontempo FA, Nedjar S. Presence of antibody to hepatitis C virus (HCV) in hemophilic men with HCV ‘seroreversion’. Blood. 1993;82:1010–1015. - PubMed
    1. Hay CRM, Preston FE, Trigger DR, Underwood JCE. Progressive liver disease in hemophilia: an understated problem? Lancet. 1985;1:1495–1498. - PubMed

Publication types

MeSH terms

Substances